Prevacus, Inc.
1400 Village Square Boulevard
Suite 3 #414
Tallahassee
Florida
32312
United States
Website: http://prevacus.com
About Prevacus, Inc.
Spun out of Florida State University, Prevacus is a development stage company focusing on a new treatment for concussions, a.k.a., mild traumatic brain injuries or mTBI. TBI touches many lives and is a major cause of disability worldwide. Particularly vulnerable are athletes, the military, the elderly and victims of motor vehicle accidents.YEAR FOUNDED:
2012
LEADERSHIP:
Founder: Jacob Vanlandinghamd
CSO: Michael Lewandowski
6 articles about Prevacus, Inc.
-
Prevacus Announces Sale of PRV-002 to Odyssey Group International
2/5/2021
Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders; today announced that it has entered into a definitive agreement for the sale of drug candidate PRV-002 to Odyssey Group International (OTCQB:ODYY).
-
Prevacus Announces Use of blinktbi's EyeStat in Upcoming Phase 1 Clinical Study
7/13/2018
Prevacus, Inc. announced a partnership with blinktbi, Inc for use of their patented device, EyeStat, in Prevacus' upcoming Phase 1 clinical research study as an objective biomarker of brain function.
-
Prevacus Partners with BrainScope for Upcoming Drug Study on Concussion
5/18/2018
Prevacus, Inc., a leading biopharmaceutical company focused on developing treatments for concussion (mild traumatic brain injury (mTBI)) and other neurological disorders today announced a partnership with BrainScope for use of their FDA-cleared BrainScope One device in Prevacus' upcoming Phase 1b clinical research study as an objective biomarker of brain function
-
Prevacus Announces The Addition Of Randy Travis To Its Advisory Board
6/26/2017
-
Prevacus Announces Appearance On Fox Business
2/15/2017
-
Prevacus To Begin Phase 1 Clinical Studies Of PRV-002 For The Treatment Of Concussion
2/10/2017